Vimarsana
Biggest News Aggregation in the World

Aleix Prat News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aleix Prat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aleix Prat Today - Breaking & Trending Today

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer, and two translational studies of PHERGain in breast cancer - Vimarsana News

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer, and two translational studies of PHERGain in breast cancer

Published: October 21, 2023

/PRNewswire/ -- MEDSIR, a company specializing in the strategic design of independent clinical research, today presented the results of three new studies at...

Source: prnewswire.com
Related Topics:
United StatesAntonio CallesAntonio Llombart CussacAleix PratJavier CortGregorio MaraDrug AdministrationAmerican Society Of Clinical OncologyEuropean Society For Medical OncologyEuropean SocietyMedical OncologyAmerican SocietyClinical OncologyPharmaceuticals Health Care Amp HospitalsMedical Pharmaceuticals Quity Amp InclusionClinical Trials Amp Medical DiscoveriesOlls And Research
Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate - Vimarsana News

Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Published: June 5, 2023

Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel

Source: finanznachrichten.de
Related Topics:
United StatesComunidad Autonoma De CatalunaMecklenburg VorpommernBruxelles CapitaleTimothy MccarthyAleix PratThomas HeinemanMartinej PiccartStefan KlotterJon PattonOncolytic Reovirus PelareorepMatt CoffeyOncolytics Biotech IncSecurities ExchangeCompany ContactAmerican Society Of Clinical OncologyClinical OncologyAnnual MeetingChief ExecutiveChief Medical OfficerInflammatory PhenotypeRichard VileMayo ClinicLibre De BruxellesSecurities Exchange Act
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate - Vimarsana News

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Published: June 5, 2023

Pelareorep-paclitaxel combination reduced risk of disease progression by 71% compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with... | June 5, 2023

Source: marketscreener.com
Related Topics:
United StatesBruxelles CapitaleComunidad Autonoma De CatalunaOncolytic Reovirus PelareorepMatt CoffeyAleix PratTimothy MccarthyThomas HeinemanJon PattonMartinej PiccartAmerican Society Of Clinical OncologySecurities ExchangeCompany ContactOncolytics BiotechOncolytics Biotech IncClinical OncologyAnnual MeetingChief ExecutiveChief Medical OfficerInflammatory PhenotypeSecurities Exchange ActCanada NewswireOncolytics Biotech Inc Stock ExchangePress ReleaseIth Onc Ca6823108759
Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting - Vimarsana News

Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

Published: May 26, 2023

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that it will host a key opinion leader webinar to discuss data from the randomized...

Source: prnewswire.com
Related Topics:
Bruxelles CapitaleComunidad Autonoma De CatalunaUnited StatesInstitut Jules BordetJon PattonTimothy MccarthyWilliaml McguireMartinej PiccartDavida KarnofskyAleix PratCharlesm PerouEuropean Society For Medical OncologyOncolytics Biotech IncUniversity Of LondonCompany ContactTherapeutics In Solid Tumors LabAmerican Society Of Clinical OncologyBreast Cancer ResearchAmerican Association For Cancer ResearchUniversity Of BarcelonaEuropean Cancer OrganisationLaboratory Of ProfUniversity Of OxfordOncolytics BiotechSpanish Breast Cancer Cooperative Research Group
Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting - Vimarsana News

Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

Published: May 26, 2023

Key opinion leader webinar to take place on June 5, 2023 at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, May 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced

Source: finanznachrichten.de
Related Topics:
United StatesComunidad Autonoma De CatalunaBruxelles CapitaleDavida KarnofskyInstitut Jules BordetJon PattonCharlesm PerouWilliaml McguireMartinej PiccartAleix PratGewinn NurTimothy MccarthyAmerican Society Of Clinical OncologyEuropean Cancer OrganisationTherapeutics In Solid Tumors LabUniversity Of BarcelonaEuropean Society For Medical OncologyUniversity Of OxfordBreast Cancer ResearchOncolytics Biotech IncAmerican Association For Cancer ResearchEuropean Organisation For ResearchBreast International GroupLaboratory Of ProfUniversity Of London